comparemela.com

Latest Breaking News On - Oncodesign group - Page 1 : comparemela.com

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV, Advised By ELYAN PARTNERS, Acquires a Majority Stake in ONCODESIGN SERVICES and Will File a Simplified Tender Offer on the Company s Remaining Shares

EDMOND DE ROTHSCHILD EQUITY STRATEGIES IV, Advised By ELYAN PARTNERS, Acquires a Majority Stake in ONCODESIGN SERVICES and Will File a Simplified Tender Offer on the Company s Remaining Shares
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Oncodesign Announces Its Results for the First Half of 2022: 28% Growth in Service Turnover

Oncodesign Announces Its Results for the First Half of 2022: 28% Growth in Service Turnover
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022

Group turnover up by 23% at €31.3 millionOperating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M)R&D investments amounting to €7.4MNet profit/loss near the break-even point (-€0.3M)Service BU:Very strong organic growth in external turnover at +31%, reaching €27.6M,EBIT.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.